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DESCRIPTION OF THE EVIDENCE COLLECTION METHOD
A search was performed in the databases EMBASE, 
SciELO/LILACS, PubMed/MEDLINE, and Cochrane Library 
using the following words: signs, symptoms, endoscopy, 
gastroesophageal reflux, GERD, heartburn, NERD, GERD, 
esophagus, hydrogen-ion concentration, esophageal pH 
monitoring, ion-selective electrodes, bravo, capsules, cap-
sule endoscopy, electric impedance, extra-esophageal, 
asthma, atypical symptoms, chest pain, cough, globus sen-
sations, hoarseness, otorhinolaryngologic diseases, pain, 
respiratory tract diseases, laryngitis, vomiting, biopsy, 
histology, dilatat*, DIS, intercellular, space*, endosonog-
raphies, echo, echo endoscopies, endoscopies, ultrasonic 
endoscopy, echo-endoscopy, echo endoscopy, echo-endos-
copies, ultrasonic, ultrasonic endoscopies, ultrasonogra-
phy, endoscopic, endoscopic ultrasonography, endoscopic 
ultrasonographies, ultrasonographies, endoscopic, endo-
sonography, sonography, pulmonary fibrosis, sleep disor-
ders. About 12,000 publications were retrieved using the 
filters: humans, sensitiv*, sensitivity and specificity, diag-
nos*, diagnosis, diagnostic, diagnosis, differential, ran-
domized controlled trial, randomized AND controlled AND 
trial, clinical AND trial, clinical trials, random*, random 
allocation, therapeutic use, epidemiologic methods, rela-
tive AND risk*, relative risk, risks, cohort studies, cohort 
AND stud*, prognos*, first AND episode, cohort. Fifty-one 
studies were selected to support this Guideline, which 
conferred the degree of recommendation A or B. These 
recommendations were adapted to our scenario. Experts 
representing major Brazilian universities including clinical 
gastroenterologists, digestive surgeons, pathologists, en-
doscopists, otolaryngologists and pulmonologists attended 
the meetings to discuss and set these guidelines.
DEGREE OF RECOMMENDATION AND STRENGTH OF THE EVIDENCE
A: Experimental or observational studies of higher 
consistency.
B: Experimental or observational studies of lower 
consistency.
C: Case reports (non-controlled trials).
D: Opinion without critical evaluation, based on con-
sensus, physiological studies, or animal models.
©2011 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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OBJECTIVES
Due to the high prevalence of gastroesophageal reflux 
disease (GERD), differences in the form of clinical pre-
sentation, economic impact, consequences of impaired 
quality of life, and  cost of clinical and laboratory re-
search, international consensus meetings have been en-
couraged.
On the other hand, the diagnostic and therapeutic 
management of GERD has varied from center to center, 
which is an important factor in the search for scientific 
evidence on the subject and served as motivation for the 
development of this Guideline, which seeks to answer 14 
questions relevant to the clinical diagnosis of GERD.
INTRODUCTION
Gastroesophageal reflux disease (GERD) is one of the 
most common disorders in medical practice. Under 
the same designation, the disease presents distinct clini-
cal conditions such as occasional heartburn, chronic 
cough, and refractory asthma. As for diagnosis, the en-
doscopic conditions are very diverse, ranging from the 
absence of injury to the presence of major complications 
such as Barrett’s esophagus.
GERD is a chronic condition resulting from the ret-
rograde flow from part of gastroduodenal contents into 
the esophagus and/or organs adjacent to it, resulting in a 
variable spectrum of esophageal/extra-esophageal signs 
and/or symptoms, with or without tissue damage.
1. SHOULD ADULT PATIENTS WITH GERD MANIFESTA-
TIONS (HEARTBURN AND/OR REGURGITATION), WITHOUT 
SYMPTOMS OR WARNING SIGNS (WEIGHT LOSS, BLEEDING, 
SORE THROAT, DYSPHAGIA ETC.) BE SUBMITTED TO UPPER 
DIGESTIVE ENDOSCOPY (UDE) BEFORE TREATMENT?
In patients with a mean age of 45 years, the presence of 
heartburn and heartburn symptoms increases the risk 
for diagnosis of GERD, odds ratio (OR): 1.9 (1.3 to 2.7) 
and 1.6 (1.0 to 2.4), respectively. And the presence of ab-
dominal pain, chest pain, and nausea symptoms reduces 
the risk for diagnosis of GERD, OR: 0.6 (0.4 to 0.9); 0.5 
(0.3 to 0.8); and 0, 7 (0.4 to 0.9), respectively (A)1. 
In patients with a mean age of 54 years, the presence 
of pyrosis (or heartburn) symptom has a sensitivity of 
67%, specificity 77%, and positive likelihood ratio of 2.83 
in the diagnosis of GERD. And the absence of pyrosis (or 
heartburn) symptom has a sensitivity of 33%, specificity 
of 24%, and negative likelihood ratio of 0.44 to exclude 
the diagnosis of GERD (A)2.
The use of the reflux disease questionnaire (RDQ) in 
patients with a mean age of 41 years, with symptoms of 
GERD, provides a sensitivity of 87.5% and specificity 
of 75.7%: positive likelihood ratio of 3.6 for diagnosis of 
GERD and negative ratio of 0.16 to exclude the diagno-
sis (A)3.
In patients with a mean age of 42 years and symptoms 
of GERD, the use of scale with seven symptoms, com-
pared to EGD, provides sensitivity, specificity, likelihood 
ratio of 74.3%, 71.6%, 2.61, and 0.36, respectively (A)4.
Symptomatic response after four weeks of empirical 
treatment with esomeprazole 40 mg (86.4%) in patients 
with GERD is equivalent to the treatment preceded by 
UDE (87.5%). Similarly, after maintenance treatment 
with esomeprazole 20  mg (24 weeks), a similar pro-
portion of patients remained responsive (71.8% versus 
68.3%), respectively (A)5.
RECOMMENDATION
In populations with GERD prevalence of 12% to 25%, 
the presence of heartburn and regurgitation symptoms 
increases the diagnostic confirmation to about 40%. The 
upper digestive endoscopy does not alter the clinical 
course when compared to empirical treatment.
2. PATIENTS WITH TYPICAL SYMPTOMS AND FREQUENCY 
GREATER THAN TWICE A WEEK FOR A PERIOD OF NOT LESS 
THAN FOUR WEEKS WITH NORMAL UPPER DIGESTIVE EN-
DOSCOPY TEST; IS IT GERD?
In patients (mean age 47 years) with symptoms of GERD 
and negative UDE, the score of symptoms classified as 
moderate and severe does not identify GERD patients; 
sensitivity of 82%, specificity of 22%, positive likelihood 
ratio of 1.05, and negative ratio of 0.81. And the test with 
lansoprazole 60 mg daily for seven days in the diagnosis of 
GERD gives a sensitivity of 97%, specificity of 6%, positive 
likelihood ratio of 1.03, and negative ratio of 0.03 (A)6. 
The use of RDQ in patients with a mean age of 41 
years with symptoms of GERD provides a sensitivity of 
87.5%, specificity of 75.7%, with positive likelihood ratio 
of 3.6 for diagnosis of GERD and negative ratio of 0.16 to 
exclude the diagnosis (A)3.
RECOMMENDATION
In patients with non-erosive GERD, with 20% preval-
ence, the use of symptom score (severe or moderate) in-
creases the diagnostic certainty by up to 40%.
3. SHOULD PATIENTS WITH HEARTBURN AND UPPER DI-
GESTIVE ENDOSCOPY SHOWING NO EROSIONS BE SUBMIT-
TED TO ESOPHAGEAL PH MONITORING TO CONFIRM THE 
DIAGNOSIS?
In patients with upper gastrointestinal endoscopy with-
out esophageal erosions, with typical symptoms of reflux, 
mean age 34.4 years, the esophageal pH-metry using a 
cut-off value of 4.5% of total time with pH  <  4 during 
a 24-hour period has a specificity of 90.4% and sensitivity 
of 93.3%, with positive likelihood ratio of 9.7 for diag-
nosis of GERD and negative ratio of 0.07 to rule out the 
diagnosis (A)7.
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RECOMMENDATION
In patients with GERD symptoms and UDE without 
esophageal erosions, therefore, with pretest probability of 
about 50%, an abnormal esophageal pH-metry defines the 
diagnosis of GERD with 90% certainty, and if normal, it 
rules out the diagnosis with certainty of about 95%.
4. IS THE WIRELESS CAPSULE FOR ESOPHAGEAL PH REG-
ISTRATION BETTER THAN CONVENTIONAL ESOPHAGEAL PH 
MONITORING FOR THE DIAGNOSIS OF GERD?
Patients in the study of wireless capsule for esophageal 
pH registration had less discomfort than those who un-
derwent conventional esophageal pH-metry, with 73% 
and 97%, respectively, reporting some discomfort by the 
end of monitoring; absolute risk reduction (ARR): 24% – 
the number needed to treat (NNT): 4%, 23%, and 45%, 
respectively, reporting a lot of discomfort (ARR = 22% - 
NNT  =  5). Patients monitored by wireless capsule for 
esophageal pH registration had less interference in daily 
activities, sleep, and work than the conventional pH-me-
try, with 14% and 82%, respectively, showing an impact on 
work (ARR: 68 % - NNT: 1) (B)8.
On average, the adverse effects were significantly lower 
in patients of wireless capsule for esophageal pH monitor-
ing than in conventional pH-metry, as well as in physical 
activities and daily work. The mean number of reflux epi-
sodes with less than 5 minutes recorded by conventional 
pH-metry (n = 129) was two times higher than the wire-
less capsule for esophageal pH monitoring (n = 53). The 
abnormal test rates were considered similar: wireless cap-
sule for esophageal pH monitoring (68%) and convention-
al pH-metry (71%) (B)9.
In the study of conventional pH-metry and wireless 
capsule for esophageal pH monitoring to diagnose GERD 
using cut-off value for esophageal acid exposure of 2.9%, 
the estimated number of patients with GERD was similar, 
42.4 % and 39.3% in 24 hours and 60.0% in 48 hours, re-
spectively. In the first 24 hours, the number of recorded 
events was significantly higher in the conventional pH-
metry (n = 40) than in the wireless capsule (n = 23) (B)10. 
RECOMMENDATION
In GERD patients, the use of wireless capsule for pH moni-
toring, when compared to conventional pH-metry, has the 
following benefits: less discomfort (NNT 4), less interfer-
ence with work activities (NNT 1), daily activities, and sleep 
activities. However, the conventional pH-metry accounts 
for about two times more reflux episodes in 24 hours. The 
rates of abnormal tests considered are similar. However, in 
our area, this diagnostic method is not widely available.
5. SHOULD ALL PATIENTS WITH ATYPICAL MANIFESTATION BE 
REFERRED TO PERFORM ESOPHAGEAL PH-METRY?
The sensitivity and specificity of esophageal pH-metry to 
diagnose GERD in patients with a mean age of 55 years, 
with history of retrosternal discomfort, non-cardiac, and 
without heartburn or regurgitation are 33.0% and 24.0%, 
respectively. The positive likelihood ratio for GERD diag-
nosis in these patients is 0.43 and the negative is 2.79 (A)2.
The prevalence GERD (diagnosed by UDE, esopha-
geal pH-metry, and impedance) in patients with atypi-
cal symptoms (hoarseness, chronic cough, and globus) is 
63.4%, and the diagnosis in these patients using pH-metry 
is 46.3%; impedance 48.8%, and the association of the two 
methods is 61.0% (B)11.
Analysis of patients with chronic cough, mean age 56 
years, using impedance/pH-metry and pH-metry revealed 
that most episodes (69.4%) occur regardless of reflux. Of 
the 30.6% episodes associated with reflux, only 15.0% (the 
cough) are preceded by GERD, which is 65.0% acid, 29% 
weakly acid, and 6.0% alkaline. Moreover, analysis of pa-
tients showed that sensitivity and specificity of pH-metry 
and/or diagnostic symptoms of GERD, compared with the 
calculation of  symptom association probability (SAP), is 
71.0% and 37.0%, respectively, with positive likelihood ra-
tio of 1.1 and negative of 0.78 (B)12. 
In patients with atypical symptoms (chronic cough) 
and esophageal pH-metry altered for acid reflux (56.2%), 
the treatment with omeprazole 40 mg daily for eight weeks 
resulted in partial response rate of 40.8% and non-re-
sponse of 55.1%. Among patients diagnosed with GERD 
and receiving no treatment, 54.5% had complete resolu-
tion of cough at the long-term follow-up (30 months). 
There was no significant difference in the association of 
reflux with cough in patients who responded and who did 
not respond to treatment (B)13.
Suspected GERD in patients (40 years old) with oto-
rhinolaringological symptoms (globus sensation, chronic 
cough, dysphonia, or sore throat) may be investigated 
with two-channel pH-metry system and compared with 
patients with typical symptoms. In patients with atypical 
symptoms, the analysis by proximal sensor showed a sig-
nificant difference, with a higher number of refluxes and 
percentage of time with pH  <  4, while the distal sensor 
analysis showed no difference in rates of reflux. In proxi-
mal sensor analysis, the proportion of patients with GERD 
with or without atypical symptoms is 61% and 22%, re-
spectively (B)14. 
In distribution of typical and atypical symptoms of 
27% and 73%, respectively, patients with typical symptoms 
have higher rates of symptoms (48%) in pH-metry associ-
ated with impedance than patients with atypical symptoms 
(25%) (B)15. 
In the investigation of patients with symptoms of 
GERD diagnosed by pH-metry and impedance, the acid 
reflux is more associated with patients with typical symp-
toms and non-acid reflux is more associated with patients 
with atypical symptoms (B)16.
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The esophageal pH-metry diagnostic test sensitivity 
(91%) and specificity (82%) can be increased in conditions 
in which the selected population of patients with GERD is 
responsive to treatment compared to nonresponsive. How-
ever, it is known that the correlation between response and 
positive pH-metry is high (true + high) and that many 
patients with atypical symptoms and negative pH-metry 
would be positive to the impedance (false - high) (B)17. 
Whereas:
1. Most atypical episodes occur regardless of reflux. 
In 15.0% of cases, the cough is preceded by reflux;
2. The use of conventional esophageal pH-metry in 
patients with chest pain of noncardiac origin has 
no value in GERD diagnosis;
3. Patients with chronic cough with normal or altered 
pH-metry may have the same therapeutic result;
4. The presence of non-acid or weakly acid reflux di-
agnosed by impedance/pH-metry is high and more 
prevalent in patients (adults = 35%) with atypical 
symptoms (globus sensation, chronic cough, dys-
phonia, or sore throat) than in patients with typical 
symptoms.
RECOMMENDATION
Conventional pH-metry in patients with atypical symp-
toms does not contribute to the diagnosis of GERD, de-
spite increasing the number of diagnoses when used with 
dual channel.
6. IN PATIENTS WITH ATYPICAL SYMPTOMS, WHAT IS THE 
CONTRIBUTION OF ESOPHAGEAL IMPEDANCE/PH-METRY?
In the investigation of patients with GERD symptoms us-
ing pH-metry and impedance, the acid reflux is more asso-
ciated with patients with typical symptoms and non-acid 
reflux with patients with atypical symptoms (B)16.
In the detection of acid reflux, the pH-metry compared 
with the impedance/pH-metry association (gold standard) 
has 68% specificity on the criterion pH < 4, and 67% when 
the criterion is the index of symptoms. The percentage 
of pH  <  4 was significantly higher in pH-metry than in 
the impedance/pH-metry association. In the detection of 
weakly acid reflux, the pH-metry has a sensibility of 28% 
when compared with the association of methods, with an 
83% rate of false-positive results (A)18.
The prevalence of GERD (diagnosed by UDE, pH-me-
try, and impedance) in patients with atypical symptoms 
(hoarseness, chronic cough and globus) is 63.4%, and the 
diagnosis in these patients by pH-metry is 46.3%, imped-
ance 48.8%, and the two associated methods 61.0% (B)11.
Analysis of patients with chronic cough, mean age 
56 years, using impedance/pH-metry revealed that most 
episodes (69.4%) occur regardless of reflux. Of the 30.6% 
episodes associated with reflux, only 15.0% (the cough) are 
preceded by GERD, which is 65.0% acid, 29% weakly acid, 
and 6.0% alkaline. Moreover, analysis of patients showed 
that sensitivity and specificity of pH-metry and/or diag-
nostic symptoms of GERD, compared with the calculation 
of  symptom association probability (SAP), is 71.0% and 
37.0%, respectively, with positive likelihood ratio of 1.1 
and negative of 0.78 (B)12. 
Whereas:
1. The non-acid or weakly acid reflux is more associ-
ated with atypical symptoms;
2. The prevalence of non-acid reflux or weakly acid 
is 35%;
3. The use of pH monitoring does not diagnose non-
acid reflux.
RECOMMENDATION
In patients with atypical symptoms, the impedance/pH-
metry can contribute to the diagnosis of GERD.
7. SHOULD PATIENTS WITH REFRACTORY GERD BE SUB-
MITTED TO ESOPHAGEAL BIOPSY?
The one-year follow-up of patients with erosive GERD 
undergoing treatment with proton-pump inhibitor (PPI) 
(eight weeks of treatment with lansoprazole 30 mg/day, 
followed by long-term treatment with lansoprazole 15 to 
30 mg/day or omeprazole 20 mg/day) revealed through 
esophageal biopsy that there is a decrease of 51% to 2% in 
high-grade hyperplasia of basal lamina, and an increase 
of 8% to 63% in the number of normal epithelium (B)19.
In patients with GERD submitted to UDE during 
follow-up treatment with PPI for 90 days, presenting 
incomplete epithelial recovery correlated with sporadic 
symptoms, the treatment with PPI may be extended, in-
creasing the response, also correlated with recovery of 
the esophageal dilatation of the intercellular space (B)20.
Despite treatment with PPI, 25% of patients with non-
erosive GERD progress to erosive in two years, grades 
A and B, according to the classification of Los Angeles 
(LA), 0.6% for C and D and 0.5% for Barrett’s esophagus. 
Of the patients who initially had LA grade C/D and A/B, 
5.8% and 1.4% of cases, respectively, progress to Barrett’s 
esophagus (B)21. 
In patients with GERD, the thickness of the lamina 
propria pretreatment is associated with the severity of 
esophagitis. After treatment with esomeprazole, the 
thickness of the basal lamina reduces significantly in pa-
tients with erosive and non-erosive GERD (particularly 
in Los Angeles classification grades C and D) (B)22. 
The use of histological change scores (hyperplasia of 
the basal lamina, dilatation of intercellular space, eosino-
philia, neutrophilia, erosion/necrosis, papillary elonga-
tion), using cut-off > 2, differentiates patients with non-
erosive GERD from healthy patients, with sensitivity and 
specificity of 76% and 85% (positive likelihood ratio of 5 
and negative of 0.28). It also differentiates patients with 
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GERD from healthy patients with sensitivity and speci-
ficity of 84% and 85% (positive likelihood ratio of 5.6, 
negative of 0.18). Note: two biopsies were performed at 
squamocolumnar junction, two at 2 cm, and two at 4 cm 
above the junction (B)23. 
In patients undergoing treatment for two years, the 
scores of histological changes not taking into account 
the expansion of the intercellular space (basal lamina hy-
perplasia, vascular dilation, eosinophils, neutrophils, pap-
illary elongation) and using a cut off value > 2, differenti-
ate GERD patients comparing symptoms and esophageal 
pH-metry, with sensitivity and specificity of 54% and 73% 
(positive likelihood ratio of 2 and negative of 0.63) (A)24.
Whereas:
In patients on long-term (1-year) PPI therapy: 
1. Histological changes may remain, regardless of 
the presence of symptoms and/or signs;
2. Histological changes may become worse;
3. The severity of esophagitis accompanies the de-
gree of histological change.
RECOMMENDATION
 The follow-up of patients on PPI therapy with persistent 
symptoms can best be established with the use of UDE 
and esophageal biopsy to identify histological signs (in-
tercellular dilation, basal lamina thickening etc.), with 
a positive and negative likelihood ratios six-fold higher 
for GERD diagnosis, which allows to establish if clinical 
treatment should be maintained or not.
8. WHAT IS THE ROLE OF THE INTERCELLULAR SPACE DILA-
TION ON ESOPHAGEAL MUCOSA EXAMINATION IN THE DIAG-
NOSIS OF GERD?
The assessment of histological changes in GERD diagnosis 
showed that dilation of intercellular space alone has sen-
sitivity and specificity of 86% and 70%, respectively, with 
positive likelihood ratio of 2.86 and negative of 0.2 (B)23.
The presence of intercellular spaces dilation in pa-
tients with GERD symptoms who underwent esopha-
geal pH-metry assessment can identify patients with 
non-erosive and erosive esophageal GERD, with a sen-
sitivity of 68.2% and 90.1%, respectively, and specific-
ity of 91.7%. The positive likelihood ratio increases the 
diagnostic probability 8.2 to 10.8-fold, respectively, and 
decreases the negative likelihood ratio 3 to 10-flod, re-
spectively (B)25. 
After three months of treatment with omeprazole 
40 mg, 92% of patients presented recovery of intercellular 
space, as well as resolution of symptoms (B)20. 
The intercellular space diameter in distal and proxi-
mal esophagus of patients with erosive and non-erosive 
GERD is 3 to 2-fold higher, respectively, than in healthy 
patients. These variations in diameter accompany the 
acid exposure time obtained during pH-metry (B)26. 
The mean diameter of intercellular spaces in patients 
with erosive and non-erosive GERD is about 4-fold high-
er than in patients without reflux (B)27. 
In patients with symptoms of reflux and chronic lar-
yngitis, the intercellular space diameter is about 3-fold 
higher than in patients without symptoms (B)28.
The intercellular space dilation in patients with GERD 
is correlated with the score of esophageal symptom and 
histological signs of esophagitis (B)29. 
RECOMMENDATION
The assessment of intercellular space diameter in esopha-
geal biopsies of patients with suspected GERD increases 
the probability of diagnostic certainty (positive likeli-
hood ratio 3 and negative 0.2). Moreover, the diameter 
allows the assessment of treatment response.
9. WHAT IS THE ROLE OF THE BASAL PROLIFERATION OF 
THE LAMINA PROPRIA IN THE DIAGNOSIS OF GERD?
The one-year follow-up of patients with erosive GERD 
undergoing treatment with PPI (eight weeks of treatment 
with lansoprazole 30  mg/day, followed by long-term 
treatment with lansoprazole 15 to 30 mg/day or omepra-
zole 20 mg/day), revealed through esophageal biopsy that 
there is a decrease of 51% to 2% in high-grade hyperpla-
sia of basal lamina, and an increase of 8% to 63% in the 
number of normal epithelium (B)19.
There is an increased risk in the presence of mini-
mal change esophagitis, such as basal cell hyperplasia 
in patients with non-erosive GERD (43.5%), compared 
to those without acid reflux (symptoms and endoscopy) 
(10.2%) — an increased risk of 33.3%. After treatment 
with PPI (esomeprazole 20  mg for 4 weeks), there was 
no difference in the prevalence of hyperplasia in both 
groups (B)30.
Analyzing the role of basal cell hyperplasia using 
measurements of sensitivity and specificity of 35% and 
71%, respectively, we find that there is little impact on the 
diagnosis of GERD (positive likelihood ratio of 1.2 and 
negative 0.91) (B)31.
During the endoscopic examination, when the biopsy 
is performed 2  cm above the Z line, there are signs of 
histologic response in measurement of lamina propria 
thickness with the use of PPI. There is no difference be-
tween patients with erosive and non-erosive GERD. And 
there is no correlation between the histological response 
and clinical improvement (B)22. 
The assessment of histological changes in GERD 
diagnosis showed that basal cell hyperplasia alone has 
sensitivity and specificity of 98% and 45%, respectively, 
with positive likelihood ratio of 1.78 and negative of 0.04, 
therefore, basal cell hyperplasia alone is more important 
to exclude the diagnosis or active disease when it is ab-
sent (B)23. 
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RECOMMENDATION 
The assessment of basal cell proliferation (BCP) in 
esophageal biopsies of patients with suspected GERD 
allows, in the absence of BCP, to exclude the diagnosis 
or disease activity (negative likelihood ratio: 0.04). How-
ever, the presence alone of BCP has little impact on diag-
nosis (positive likelihood ratio: 1.78). Although basal cell 
thickness allows the analysis of therapeutic response (in 
the absence), it is not correlated with clinical signs.
10. WHAT IS THE ROLE OF ENDOSCOPIC ULTRASOUND IN 
THE DIAGNOSIS OF GERD?
There are significant differences in esophageal wall thick-
ness between patients with erosive and non-erosive 
GERD evaluated by endoscopic ultrasound, with in-
volvement of the distal wall of the lesions. There is no 
correlation between duration of symptoms and degree of 
thickening (B)32. 
In patients with erosive GERD, there is correlation be-
tween structural changes in the wall of the lower esopha-
gus identified by endoscopic ultrasound and functional 
impairment of the esophagus (pressure) (B)33. 
RECOMMENDATION
There is limited scientific information and with little con-
sistency evaluating the use of endoscopic ultrasound in 
esophageal wall structural changes in patients with ero-
sive GERD, with no clinical application at present.
11. SHOULD PATIENTS WITH ASTHMA BE INVESTIGATED FOR 
GERD?
Frequent regurgitation (greater than once per week) or 
excessive acid reflux in proximal esophagus (greater than 
1.1% of the total time of dual channel esophageal pH-metry) 
can predict 20% improvement in asthma symptoms, with 
daily omeprazole 20, 40, or 60  mg for three months, 
with 100% sensitivity and specificity of 44%, reflecting 
the certainty of response with a positive likelihood ratio 
of 1.78, and negative of 0 (zero) (B)34. 
Therapy with pantoprazole 40 mg daily for 12 weeks 
showed improvement of symptoms and quality of life with 
no impact on respiratory function tests in patients 
with asthma and respiratory symptoms related to gastro-
esophageal reflux (A)35. 
Omeprazole 20  mg twice daily and domperidone 
10 mg three times daily for 16 weeks reduces the score 
of morning symptom by 8.5% (17.4% vs 8.9%), nighttime 
symptoms by 14.2 % (19.6% vs 5.4%), and reflux symp-
toms by 7.1% (8.7% vs 1.6%) (A)36. 
The use of lansoprazole 30  mg twice daily for 24 
weeks in patients with asthma and gastroesophageal re-
flux reduces the risk of asthma exacerbation in 12.3% — 
NNT = 8 (A)37. 
In asthmatic patients, the prevalence of gastroesopha-
geal reflux symptoms can be up to 82%. Symptoms of re-
flux have 92% sensitivity and specificity of 35% in the di-
agnosis of GERD in asthmatic patients with and without 
esophageal pH changes (positive and negative likelihood 
ratios of 1.41 and 0.22, respectively) (A)38.
In patients with and without reflux symptoms and ab-
normal pH, the presence of wheezing has a sensitivity and 
specificity of 65% and 58% (positive and negative likeli-
hood ratios of 1.54 and 0.60, respectively) and the pres-
ence of cough has a sensitivity and specificity of 98% and 
72% (positive and negative likelihood ratios of 3.5 
and 0.02, respectively) (A)38. 
RECOMMENDATION
The presence of reflux symptoms in some patients with 
asthma slightly increases the likelihood of diagnostic cer-
tainty. In patients with GERD, PPI therapy has NNT of 8 
for reducing exacerbation of asthma symptoms. In asth-
matic patients with reflux symptoms, normal pH monitor-
ing predicts the lack of therapeutic response.
12. SHOULD PATIENTS WITH INTERSTITIAL LUNG DISEASE 
(PULMONARY FIBROSIS) BE INVESTIGATED FOR GERD?
In patients with idiopathic pulmonary fibrosis, 67% have 
gastroesophageal reflux. Typical symptoms of reflux have a 
sensitivity of 65% and specificity of 71% for diagnosing 
GERD. The positive and negative likelihood ratios are 2.24 
and 0.49, respectively (A)39. 
Prevalence of GERD in patients with idiopathic pul-
monary fibrosis can be up to 87%, but only 47% of these 
patients had symptoms of reflux (A)40. 
The prevalence of GERD in asthma patients may be 
lower (68%); and patients with pulmonary fibrosis may 
have more gastroesophageal reflux at the distal region of the 
esophagus than patients with asthma (76% vs 57%) (A)40. 
The risk of GERD in patients with pulmonary fibrosis 
may be up to 94.1%, compared with patients without fi-
brosis in which the risk is 50%. Only 25% of patients have 
typical reflux symptoms (B)41. 
RECOMMENDATION
The association of pulmonary fibrosis in GERD is high. 
Typical symptoms of reflux in these patients slightly in-
crease the likelihood of diagnostic certainty.
13. SHOULD PATIENTS WITH APNEA AND/OR SLEEP DISOR-
DERS BE INVESTIGATED FOR GERD?
Patients with sleep apnea have more events of GERD in 8 
hours than patients without sleep apnea and a longer time 
of pH < 4.0 during esophageal pH-metry examination. In 
patients with sleep apnea, 53.4%  of reflux episodes are re-
lated to apnea and hypopnea, and 46.8% of all apneas are 
related to reflux episodes (B)42.
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Symptoms Sensitivity (%) Specificity (%) Positive ratio Negative ratio
Cough 31 53 0.65 1.30
Globus 3 91 0.33 1.06
Hoarseness 44 67 1.35 0.82
Sore throat 10 88 0.83 1.02
Table 1 – GERD-associated symptoms
In patients being evaluated for sleep disorders, the 
evaluation by RDQ identified 12.8% of patients with 
GERD. Excessive sleepiness is associated with severity 
of GERD symptoms. Patients with GERD had more day-
time sleepiness (B)43.
Using the GERD Symptom Assessment Score (GSAS) 
and the questionnaire Sleep Heart Health Study (SHHS) 
for assessing sleep habits, there was a positive association 
between sleep disorders and severity of index symptoms. 
A greater number of awakenings during sleep is also as-
sociated with higher rates of GERD symptoms. It was also 
observed that the poor quality of sleep is related to a great-
er number of reflux events in the pH-metry (B)44. 
Heartburn or regurgitation is not related to apnea se-
verity in patients with sleep apnea (B)45. 
In patients with sleep apnea, about 81% of all acid 
events are associated with respiratory events (apnea or 
hypopnea), although there is no correlation between the 
magnitude of the events and apnea-hypopnea index (B)46.
RECOMMENDATION
There is association between GERD and apnea and/or sleep 
disorders. There is direct correlation between the intensity 
of GERD symptoms and sleep disorders. There is no direct 
correlation between the intensity of GERD symptoms and 
sleep apnea. However, there is direct correlation between 
acid reflux events, sleep disorders, and apnea.
14. SHOULD PATIENTS WITH SIGNS SUGGESTIVE OF POSTE-
RIOR LARYNGITIS BE INVESTIGATED FOR GERD?
The symptoms (hawk, cough, globus, sore throat, or 
hoarseness) of patients with chronic posterior laryngitis 
does not improve with the use of esomeprazole 40 mg dai-
ly for 16 weeks compared with placebo (A)47. 
After three months of treatment with lansoprazole 
30 mg, there was no difference in the number of patients 
with chronic laryngitis achieving partial or total resolution 
of symptoms (cough, globus, sore throat, or hoarseness) 
compared with placebo (A)48. 
In patients with symptoms of chronic laryngitis, com-
pared to those with symptoms of heartburn and/or regur-
gitation, there is a discrepancy between symptoms and 
reflux parameters (on esophageal pH-metry test). Thirty-
three percent of patients with laryngitis have significant 
reflux, but with no typical symptoms of reflux. Laryngo-
pharyngeal reflux episodes occurred with no difference 
between patients with symptoms of laryngitis and typical 
symptoms of reflux. Gastroesophageal reflux episodes in 
distal esophagus on esophageal pH-metry also occurred 
with no difference between the two groups (B)49. 
There is no correlation between chronic laryngitis 
symptoms and laryngeal reflux grade. Heartburn was 
worse in the group with laryngeal reflux than in patients 
without reflux. In addition, the patients with laryngeal 
reflux had more distal reflux (number of episodes and 
percentage of time with pH < 4 on esophageal pH-metry) 
than patients without laryngeal reflux (B)50. 
The symptoms of chronic laryngitis when compared 
to the pH-metry alone in the diagnosis of GERD provide 
likelihood ratio insufficient to increase the diagnostic cer-
tainty (Table 1) (B)51. 
The positive likelihood ratio < 1 and the negative > 1 
define signs and symptoms that hinder the diagnosis of 
GERD (B)51. 
RECOMMENDATION
The response to PPI therapeutic test in patients with chronic 
laryngitis symptoms (cough, globus, sore throat or hoarse-
ness) does not increase the likelihood alone of GERD di-
agnosis. The occurrence of symptoms of chronic laryngitis 
and typical of gastroesophageal reflux is not associated with 
the frequency and intensity of acid reflux (Figure 1).
Heartburn/Regurgitation  
(prevalence 20%)
(-)
UED
Tests
Biopsy
Optical Electronics
Exclude 
GERD
pH-metry Therapeutic trial
Impedance
GERD
GERD
GERD
GERD  
(non-acid reflux)
GERD (-) (-)
(-) (-)
(+)
(+)
(+)
(70%)
(70%) (90%)
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(50%)
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Figure 1 – Diagnostic flowchart of gastroesophageal reflux 
disease
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